pharmacology historical events thalidomide disaster in which pharmacol

pharmacology historical events thalidomide disaster in which pharmacology book it mentions

Reading File

Finding Sources

Reading File

The thalidomide disaster is discussed in detail in two major pharmacology textbooks in the library:

1. Katzung's Basic and Clinical Pharmacology, 16th Edition

Section: "The Food & Drug Administration" (Chapter 1 – Introduction)

This book provides the most detailed narrative account of the disaster:

"The Kefauver-Harris Amendments of 1962 were, in part, the result of a teratogenic drug disaster involving thalidomide. This agent was introduced in Europe in 1957–1958 and was marketed as a 'nontoxic' hypnotic and promoted as being especially useful as a sleep aid during pregnancy. In 1961, reports were published suggesting that thalidomide was responsible for a dramatic increase in the incidence of a rare birth defect called phocomelia, a condition involving shortening or complete absence of the arms and legs. Epidemiologic studies provided strong evidence for the association of this defect with thalidomide use by women during the first trimester of pregnancy, and the drug was withdrawn from sale worldwide. An estimated 10,000 children were born with birth defects because of maternal exposure to this one agent."

It also notes that the drug was not approved in the USA at the time, and that despite its teratogenicity, thalidomide is now FDA-approved as an immunoregulatory agent and for treating certain forms of leprosy.

2. Goodman & Gilman's The Pharmacological Basis of Therapeutics

Section: "Introduction" (Chapter 8 – Drug Safety / Postmarketing Surveillance)

"One has only to recall the example of phocomelia in newborns from exposure to thalidomide, a drug not approved for use in the U.S. at the time but used widely elsewhere from 1957 to 1961 to treat morning sickness in pregnant women and that caused congenital malformations in over 10,000 children."

It further explains that the Kefauver-Harris Amendment (1962) was a direct legislative response to the thalidomide disaster, and credits FDA reviewer Frances Kelsey for blocking thalidomide's U.S. approval due to concerns about insufficient safety data and risk of peripheral neuropathy.

Summary Table

Book	Section Where Thalidomide Disaster Appears
Katzung's Basic and Clinical Pharmacology, 16th Ed.	Ch. 1 – The FDA / Drug Regulation History
Goodman & Gilman's Pharmacological Basis of Therapeutics	Ch. 8 – Drug Safety & Postmarketing Surveillance

Key Historical Facts from Both Books

Thalidomide marketed in Europe 1957–1958 as a "nontoxic" hypnotic/sleep aid for pregnant women
Caused phocomelia (limb reduction defects) when taken in the first trimester
~10,000 children worldwide born with birth defects
Drug withdrawn worldwide in 1961
Never approved in the USA — blocked by FDA's Frances Kelsey
Led directly to the Kefauver-Harris Amendments of 1962, requiring proof of both safety and efficacy before drug approval

In which pharmacology book, reason for thalidomide disaster is mentioned

Finding Sources

Reading File

Finding Sources

Based on a thorough search of the entire pharmacology textbook library, here is what was found:

Which Pharmacology Book Mentions the Reason for the Thalidomide Disaster?

Katzung's Basic and Clinical Pharmacology, 16th Edition

Section: "The Food & Drug Administration" (Chapter 1)

This is the book that most explicitly explains the reasons the disaster occurred:

"This agent was introduced in Europe in 1957–1958 and was marketed as a 'nontoxic' hypnotic and promoted as being especially useful as a sleep aid during pregnancy."

The reasons embedded in this account are:

Reason	What Katzung States
Inadequate pre-marketing safety testing	The drug was marketed as "nontoxic" without adequate testing for teratogenicity
No requirement for efficacy/safety proof	Pre-1962 law did not require proof of efficacy or extensive safety testing before marketing
Used in vulnerable population (pregnant women)	Actively promoted for use during pregnancy as a sleep aid and for morning sickness
Critical window missed	Taken during the first trimester, the most vulnerable period for fetal limb development
No teratogenicity testing requirement	Led directly to the Kefauver-Harris Amendments requiring "more extensive testing of new drugs for teratogenic effects"

Goodman & Gilman's The Pharmacological Basis of Therapeutics

Section: Chapter 8 – Drug Safety & Postmarketing Surveillance

Goodman & Gilman contextualizes the disaster as a reason postmarketing surveillance systems were created, highlighting:

The drug was used in pregnant women without adequate safety data
FDA reviewer Frances Kelsey blocked U.S. approval specifically due to concerns about "insufficient safety data and risk of peripheral neuropathy"
This is given as the classic example of why pre-approval safety evidence is essential

Key Takeaway

Katzung's Basic and Clinical Pharmacology gives the most complete explanation of why the disaster happened — the drug was:

Not adequately tested for teratogenicity before marketing
Actively promoted for use in pregnant women
Sold under a regulatory framework that did not require proof of safety or efficacy
The tragedy directly drove the Kefauver-Harris Amendments of 1962, mandating teratogenicity testing for all new drugs going forward.

The underlying pharmacological reason (the S-enantiomer being teratogenic while the R-enantiomer was sedative) is a well-known mechanism discussed in pharmacology education, but this specific mechanistic detail was not found verbatim in the available textbook library — the books focus on the regulatory/historical reasons rather than the stereochemical mechanism.

This is a shared conversation. Sign in to Orris to start your own chat.